Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS): later-stage trial registry
1 of 1 indexed Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #11,370 of 28,707 conditions by registered trial count.
1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count
Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS): 1 US clinical trial tracked, 1 recruiting.
Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Institut de Recherches Internationales Servier, running 1 of these trials.
Enrollment posture brief
Registry condition hypomethylating-agent-hma-naive-myelodysplastic-syndromes-mds
OPEN 1 | RECR 100% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) is recruiting above its size-band peers.
1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
1 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) page
1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Institut de Recherches Internationales Servier sponsors the most Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) trials on record, review their full trial history before evaluating a specific study. See Institut de Recherches Internationales Servier's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) condition card totals 1 registered trials; most-linked intervention Ivosidenib; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.